IL33 and colorectal carcinoma: On the other hand, genetic deficiency of IL-25 or rIL-25 treatment did not alter tumour Treg frequency in Apc1322T/+ mice (81), suggesting that tumour Tregs preferentially respond to IL-33 and not IL-25 in CRC.